Value Drug plausibly alleges Alkermes duped USPTO, judge says in antitrust suit
Value Drug has plausibly alleged global biopharmaceutical company Alkermes violated federal antitrust law by protecting its monopoly on the drug naltrexone through material misrepresentations to the US Patent and Trademark Office,...To view the full article, register now.
Already a subscriber? Click here to view full article